Drugs based on MetrioPharms exclusive patented MP1000-class can be potentially applied against many different infectious and inflammable illnesses. This whidespread working profile results from the ingridient's effect to central mechanisms of the overreaction of the immune system which takes effect at all these illnesses (p. working principle MP1021).
The effectiveness of MP1021 has been proved in numerous experimental and clinical studies. The successful approval of the active ingredient in Russia and other countries is based on this studies.
MP1021 is applied successfully for the therapy of these illnesses:
The excessive activation of macrophages is one of the main causes for the pathogenese of many infectiously, inflammably and autoimmune illnesses. An effective blocking of the overshooting macrophage activity and therewith a blocking of zytokines like TNF alpha and Il 1 presents a new, potentially very effective therapy against many serious illnesses.
In the following chronic illnesses this mechanism is sgnificant: